Janney Montgomery Scott LLC Acquires New Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Janney Montgomery Scott LLC acquired a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 52,708 shares of the company's stock, valued at approximately $793,000. Janney Montgomery Scott LLC owned 0.11% of Pacira BioSciences at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PCRX. GAMMA Investing LLC raised its stake in Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after acquiring an additional 932 shares in the last quarter. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences during the second quarter valued at about $46,000. Innealta Capital LLC acquired a new stake in Pacira BioSciences in the second quarter worth about $50,000. nVerses Capital LLC grew its position in Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock valued at $51,000 after buying an additional 1,600 shares in the last quarter. Finally, Natixis acquired a new position in Pacira BioSciences during the 1st quarter valued at about $95,000. 99.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PCRX shares. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Pacira BioSciences in a research note on Friday, November 8th. Raymond James downgraded shares of Pacira BioSciences from an "outperform" rating to a "market perform" rating in a report on Monday, August 12th. Truist Financial downgraded shares of Pacira BioSciences from a "buy" rating to a "sell" rating and dropped their target price for the stock from $30.00 to $8.00 in a report on Tuesday, August 13th. Jefferies Financial Group upped their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. Finally, Barclays cut their target price on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $23.50.

Pacira BioSciences Stock Up 0.2 %

Pacira BioSciences stock traded up $0.04 during mid-day trading on Monday, reaching $16.64. The company's stock had a trading volume of 621,553 shares, compared to its average volume of 856,064. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The business's 50 day simple moving average is $15.81 and its 200 day simple moving average is $20.60. The company has a market capitalization of $768.32 million, a price-to-earnings ratio of -8.18 and a beta of 0.82. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.